Ren Luo, MD PhD

MD, PhD. Radiation oncologist.

[Ren Luo, MD PhD @RenLuo_RAD]

Chinese Expert Consensus on Low-Dose Radiotherapy

🔹 Optimal dose: 0.5–2 Gy/fraction (≤10 Gy)

🔹 ICI timing: LDRT 1–7 days before or concurrent with ICIs.

🔹 Novel strategies: LDRT+SBRT for multiple lesions; SBRT embedded within LDRT for bulky tumors.

https://t.co/kvhbd0avbE

[Ren Luo, MD PhD @RenLuo_RAD]

Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase I Trial
Safe and effective!
https://t.co/dsKF5VmJaC

[Ren Luo, MD PhD @RenLuo_RAD]

Six year's work!!! Finally published. Heterogeneous RT-(SBRT embedded in low-dose RT plus aPD-1 (immuno-EclipseRT, iERT)) elicits CD8t T cell immunity against bulky tumors via an IFN-I/NK/DC axis.
https://t.co/tNPcaA2mtL

[Ren Luo, MD PhD @RenLuo_RAD]

Proud to share our iEclipseRT (heterogeneous RT plus ICB) abstract ranked in the top 5% at #ESTRO2026 !😎

[Ren Luo, MD PhD @RenLuo_RAD]

https://t.co/QxXLQNEfrU
Our recent review also discussed the use of heterogeneous RT to minimize damage to the tumor-regional immune microenvironment.

[Ren Luo, MD PhD @RenLuo_RAD]

Immuno-EclipseRT (iERT), which combines low-dose RT to the whole tumor, partial-tumor SBRT and PD-1 blockade, controls bulky tumors via an IFN-I driven XCL1⁺ NK/cDC/CD8⁺ T cell axis. iERT is safe and effective in patient's (＞100 pts). #ESTRO26

[Ren Luo, MD PhD @RenLuo_RAD]

Immuno-EclipseRT (iERT), which combines low-dose RT to the whole tumor, partial-tumor SBRT and PD-1 blockade, controls bulky tumors via an IFN-I driven XCL1⁺ NK/cDC/CD8⁺ T cell axis. iERT is safe and effective in patient's (＞100 pts). #ESTRO26

[Ren Luo, MD PhD @RenLuo_RAD]

3/3 link
https://t.co/ReKkLPGoAE

[Ren Luo, MD PhD @RenLuo_RAD]

1/3 Our work just published in Signal Transduction Targeted Ther! Combining low-dose radiotherapy (LDRT) to bulky lesions, high-dose SBRT to small lesions, and PD-1 blockade, showed encouraging durable survival (mOS 51.3 months) in advanced NSCLC.

[Ren Luo, MD PhD @RenLuo_RAD]

2/3 Mechanistically, LDRT induced IFN-γ and GM-CSF to program TNF-α⁺ antitumor neutrophils, while CXCL–CXCR2 signaling drove them to distant tumors. There, these neutrophils supported CD8⁺ T-cell function through an ICAM-1–LFA-1 axis within a specialized neutrophil–CD8 niche.

[Ren Luo, MD PhD @RenLuo_RAD]

3/3 link https://t.co/ReKkLPGoAE

[Ren Luo, MD PhD @RenLuo_RAD]

2/3 Mechanistically, LDRT induced IFN-γ and GM-CSF to program TNF-α⁺ antitumor neutrophils, while CXCL–CXCR2 signaling drove them to distant tumors. There, these neutrophils supported CD8⁺ T-cell function through an ICAM-1–LFA-1 axis within a specialized neutrophil–CD8 niche.

[Ren Luo, MD PhD @RenLuo_RAD]

Nice to meet Prof. David Planchard @dplanchard and meet Super panda star Huahua in Chengdu, Sichuan!

[Ren Luo, MD PhD @RenLuo_RAD]

So good to meet the experts and colleagues here in #ASTRO24 @zach_buchwald @JoeChangMD @AncaGrosu1

[Vivian Tan MD @drviviantan]

👤 NRG-HN005 presented during plenary at #ASTRO2024 #radonc @sueyom

1️⃣ Arm 1: 70 Gy + cisplatin - PFS 98.1%
2️⃣ Arm 2: 60 Gy + cisplatin - PFS 88.6%
3️⃣ Arm 3: 60 Gy + nivolamab - PFS 90.3%

➡️ SOC remains 70 Gy + cisplatin

[Ren Luo, MD PhD @RenLuo_RAD]

@GabiNiedermann Thanks Gabi!

[Ren Luo, MD PhD @RenLuo_RAD]

Happy to get 35under35 of Chinese Society of Clinical Oncology 2024!

[Cancer Cell @Cancer_Cell]

Online Now: Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors https://t.co/ZmHZ9oQS45

[David Kirsch, MD, PhD @DKirschMDPhD]

Thanks @AngelaHong!! We could not have completed accrual to our trial (in 6 years!!) without your amazing accrual in Sydney and by our other colleagues in Australia.